Hyun Kim, MD
Pulmonary Disease · Boston, MANPI 1881033108
Payments from drug & device makers
What this record shows
This record is dominated by education: $71,643 of the $116,805 with a category attached, or 61.3%. Intuitive Surgical accounts for 89.0% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $57,302, more than ten times the $125 reported in 2019. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $1692.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$104K
- Boston Scientific$13K
- AstraZeneca$168
- Steris Corporation$133
What the payments were for
- Speaking & faculty fees$23,00020%
- Grants$12,50011%
- Travel & lodging$8,4687%
- Food & beverage$1,1931%
- Education$71,64361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 65 | $104,003 |
| Boston Scientific | 1 | $12,500 |
| AstraZeneca | 2 | $168 |
| Steris Corporation | 1 | $133 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$100,244
- GENERAL - BILIARY DEVICES$12,500
- ION$3,000
- DA VINCI SP$500
- TRUFREEZE$133
- IMFINZI$125
How this compares
$116,805 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $31,012 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $14,705 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,254 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,509 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 86 | $2,259 |
| Prednisone | 32 | $208 |
| Azithromycin | 20 | $89 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
- Kelsey SackBoston$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.